15 completed, 1 suspended, 1 withdrawn. 7 Phase 1, 7 Phase 2, 6 Phase 3.
By phase and status
Follow Biodel: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|
A Study Evaluating Safety and Efficacy of BIOD 531 Compared to Humalog® Mix 75/25 in Subjects With Type 2 Diabetes
BIOD-531, Humalog® Mix 75/25 - Diabetes Mellitus | Phase 2 | Suspended | Biodel | 13 | 2015-05-01 | 2016-04-07 |
Pharmacokinetics and Pharmacodynamics of BIOD-961 vs. Marketed Glucagons
BIOD-961, Lilly Glucagon, Novo Glucagon - Hypoglycemia | Phase 1 | Completed | Biodel | 15 | 2014-11-01 | 2016-01-15 |
BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500 Post-Meal Glucose Control in Patients With Severe Insulin Resistance
BIOD-531, Humalog Mix 75/25, Humulin R U-500 - Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Biodel | 12 | 2014-05-01 | 2016-02-08 |
Comparison of Postprandial Glucose Control Associated With BIOD-531 vs. Humalog Mix 75/25 vs. Humulin R U-500
BIOD-531, Humalog Mix 75/25, Humulin R U-500 - Type 2 Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Biodel | 12 | 2014-05-01 | 2016-02-08 |
Pharmacokinetic and Injection Site Toleration of BIOD-238 and BIOD-250 Compared to Humalog® in Subjects With Type 1 Diabetes
Insulin LISPRO - Type 1 Diabetes | Phase 1 | Completed | Biodel | 12 | 2012-08-01 | 2013-03-15 |
A Study Evaluating Safety and Efficacy of BIOD-123 Compared to Insulin Lispro (Humalog®)
BIOD-123, Lispro (Humalog) - Type 1 Diabetes Mellitus | Phase 2 | Completed | Biodel | 132 | 2012-08-01 | 2015-07-28 |
Pharmacokinetic and Pharmacodynamic Properties of BIOD-123 and BIOD-125 Compared to Humalog® in Subjects With Type 1 Diabetes Including Assessments of Injection Site Toleration
BIOD-123, BIOD-125, Humalog - Diabetes Mellitus | Phase 1 | Completed | Biodel | 12 | 2012-02-01 | 2013-07-26 |
Pharmacokinetic and Pharmacodynamic Properties of BIOD-105 and BIOD-107 Compared to Humalog® in Subjects With Type 1 Diabetes
Insulin LISPRO, recombinant human insulin - Diabetes Mellitus Type 1 | Phase 1 | Completed | Biodel | 13 | 2011-03-01 | 2013-07-26 |
A Randomized Control Trial Comparing Linjeta Versus Humalog in Pumps: Effect on Postprandial Blood Sugars.
LINjeta U-100 Insulin, Humalog U-100 - Diabetes Mellitus | Phase 2 | Withdrawn | Stanford University | | 2010-04-01 | 2017-02-10 |
To Evaluate the Effect on Post-prandial Glycemia Safety, and Tolerability of Viaject 7 vs. Lispro Insulin During Subcutaneous Insulin Pump Therapy
Viaject 7, LISPRO - Type 1 Diabetes Mellitus | Phase 3 | Completed | Biodel | 20 | 2010-02-01 | 2015-08-03 |
A Study Evaluating the Bioequivalence of VIAject®7 Compared to VIAject®25 and Comparing the Pharmacokinetic and Pharmacodynamic Properties of VIAject®7 to Insulin Lispro in Subjects With Type 1 Diabetes Mellitus
VIAject®25, VIAject®7, Insulin Lispro - Diabetes Mellitus | Phase 1 / Phase 2 | Completed | Biodel | 43 | 2009-07-01 | 2015-07-29 |
Effect of Treatment With Insulin VIAjectTM Compared to Regular Human Insulin and Insulin Lispro on Mealtime Blood Vessel Stress in Patients With Type 2 Diabetes Mellitus.
Regular Human Insulin, Insulin Lispro, Insulin VIAject™ (75%) - Type 2 Diabetes | Phase 3 | Completed | Biodel | 15 | 2008-04-01 | 2015-08-03 |
An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 2 Diabetes Mellitus
VIAject™ - Diabetes Mellitus | Phase 3 | Completed | Biodel | 116 | 2007-07-01 | 2015-07-29 |
An Open Label, Multi-Center, Follow-on Study Examining the Long-Term Safety and Efficacy of Insulin VIAject™ in Subjects With Type 1 Diabetes Mellitus
VIAject™ - Diabetes Mellitus | Phase 3 | Completed | Biodel | 233 | 2007-04-01 | 2015-07-29 |
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 2 Diabetes Mellitus
VIAject™, Regular Human Insulin - Type 2 Diabetes Mellitus | Phase 3 | Completed | Biodel | 472 | 2006-12-01 | 2015-08-18 |
An Open Label, Multi-Center, Randomized, Parallel Group Study Comparing the Efficacy and Safety of Insulin VIAject™ and Regular Human Insulin in Patients With Type 1 Diabetes Mellitus
VIAject™, Regular Human Insulin - Type 1 Diabetes Mellitus | Phase 3 | Completed | Biodel | 462 | 2006-09-01 | 2015-08-03 |
A Study Comparing the Pharmacodynamic Properties of Insulin VIAJECT™, Regular Human Insulin, and Insulin Lispro
Regular Human Insulin, Lispro, VIAject - Diabetes Mellitus | Phase 2 | Completed | Biodel | 24 | 2006-06-01 | 2015-07-29 |
Conditions studied
Diabetes Mellitus (10) · Diabetes Mellitus, Type 1 (5) · Diabetes Mellitus, Type 2 (3) · Insulin Resistance (2) · Hypoglycemia (1)
Interventions
Insulin Lispro (8) · Insulin (6) · Insulin Glargine (1)
Countries
United States (8) · Germany (2)
Top investigators
David C Klonoff, M.D., F.A.C.P. (2) · Linda Morrow, MD (2) · Alan Krasner, MD (1) · Bruce A. Buckingham (1) · Laurie Han-Conrad, MD (1) · Marcus Hompesch, MD (1) · Thomas Forst, MD (1) · Tim Heise, M.D (1)